Wanbury Ltd
WANBURY
Company Profile
Business description
Wanbury Ltd is engaged in the business of pharmaceutical and related activities, including research. Some of the company's products include Cpink 50mg tablets, Rabiplus capsules, and Folinine softgels, among others. The company has one segment of activity, namely, Pharmaceuticals and related products. It generates revenue from contracts with customers through the sale of manufactured and traded goods. Geographically, key revenue is generated from outside India.
Contact
Sector 30-A
10th Floor, BSEL Techpark, B Wing
Opposite Vashi Railway Station
Vashi
Navi MumbaiMH400703
INDT: +91 2267942222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
1,382
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,146.20 | 19.70 | -0.21% |
| CAC 40 | 8,430.79 | 16.48 | -0.20% |
| DAX 40 | 24,934.67 | 24.26 | 0.10% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,508.61 | 14.40 | 0.14% |
| HKSE | 23,989.17 | 322.99 | -1.33% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 71,087.66 | 1,185.41 | 1.70% |
| NZX 50 Index | 13,374.20 | 18.78 | -0.14% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,927.20 | 21.50 | -0.24% |
| SSE Composite Index | 4,115.28 | 7.21 | 0.18% |